Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Verastem, Inc.VSTM · Entity 5242 | Chief Medical Officer | September 24, 2018 | October 02, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Verastem, Inc.
Report date September 24, 2018 · Filed October 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.97 · Expires 2028-01-05 | Direct | 5,000 |
Reported balance
After 2018-09-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-09-24 · Grant · Acquired 5,000 · Balance 5,000 F1: On January 5, 2018, the Reporting Person was granted an option to purchase 12,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance milestones by June 30, 2018, by March 31, 2019, and within the first twenty-four (24) months after the achievement of certain net sales targets. 20% of the performance criteria was met on April 6, 2018, resulting in vesting of the option as to 2,500 shares. 40% of the performance criteria was met on September 24, 2018, resulting in vesting of the option as to 5,000 shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.63 · Expires 2027-10-09 | Direct | 70,000 |
Reported balance
After 2018-09-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-09-24 · Grant · Acquired 70,000 · Balance 70,000 F2: On October 9, 2017, the Reporting Person was granted an option to purchase 70,000 shares of common stock, to vest in full upon the Issuer's satisfaction of certain performance milestones. Such performance criteria were met on September 24, 2018, resulting in the vesting of the option. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 5, 2018, the Reporting Person was granted an option to purchase 12,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance milestones by June 30, 2018, by March 31, 2019, and within the first twenty-four (24) months after the achievement of certain net sales targets. 20% of the performance criteria was met on April 6, 2018, resulting in vesting of the option as to 2,500 shares. 40% of the performance criteria was met on September 24, 2018, resulting in vesting of the option as to 5,000 shares.
F2: On October 9, 2017, the Reporting Person was granted an option to purchase 70,000 shares of common stock, to vest in full upon the Issuer's satisfaction of certain performance milestones. Such performance criteria were met on September 24, 2018, resulting in the vesting of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2018 Filed Oct 2, 2018 18:51 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0000904454-18-000628 · edgar.xml · derivative · entry 2 Le NgocDiep T. MD, PhD · CIK 0001719331 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2027-10-09 F2 · shares: On October 9, 2017, the Reporting Person was granted an option to purchase 70,000 shares of common stock, to vest in full upon the Issuer's satisfaction of certain performance milestones. Such performance criteria were met on September 24, 2018, resulting in the vesting of the option. Read SEC document |
| September 24, 2018 Filed Oct 2, 2018 18:51 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0000904454-18-000628 · edgar.xml · derivative · entry 1 Le NgocDiep T. MD, PhD · CIK 0001719331 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-01-05 F1 · shares: On January 5, 2018, the Reporting Person was granted an option to purchase 12,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance milestones by June 30, 2018, by March 31, 2019, and within the first twenty-four (24) months after the achievement of certain net sales targets. 20% of the performance criteria was met on April 6, 2018, resulting in vesting of the option as to 2,500 shares. 40% of the performance criteria was met on September 24, 2018, resulting in vesting of the option as to 5,000 shares. Read SEC document |
| April 06, 2018 Filed Jun 4, 2018 17:56 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0001104659-18-038056 · a4.xml · derivative · entry 1 Le NgocDiep T. MD, PhD · CIK 0001719331 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2028-01-05 F1 · balance_after: On January 5, 2018, the Reporting Person was granted an option to purchase 12,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance milestones by June 30, 2018, by March 31, 2019, and within the first twenty-four (24) months after the achievement of certain net sales targets. 20% of the performance criteria was met on April 6, 2018, resulting in vesting of the option as to 2,500 shares. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 17:50 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0001104659-18-001513 · a4.xml · derivative · entry 1 Le NgocDiep T. MD, PhD · CIK 0001719331 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-01-05 F1 · derivative.exercise_date: 25% of this option will vest on January 1, 2019 and 6.25% of this option will vest at the end of each successive three-month period thereafter until January 1, 2022. Read SEC document |
| October 09, 2017 Filed Oct 11, 2017 20:34 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001104659-17-061846 · a4.xml · derivative · entry 1 Le NgocDiep T. MD, PhD · CIK 0001719331 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2027-10-09 F1 · derivative.exercise_date: 25% of this option will vest on October 9, 2018 and 6.25% of this option will vest at the end of each successive three-month period thereafter until October 9, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.